Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Domperidone suspension | Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. |
|
|
Domperidone tablets | Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. |
|
 |
Domperidone tablets | For short term use only |
|
 |
Donepezil orodispersible tablets | ||
|
Donepezil tablets | ||
|
Dopamine injection | Hospital use only |
|
|
Dornase alpha nebuliser solution (Pulmozyme) | NHS England commissioned for cystic fibrosis only |
|
|
Dorzolamide 2% single use eye drops (SDU) | Specialist ophthalmologist recommendation |
|
|
Doxapram injection | Hospital only |
|
|
Doxepin hydrochloride cream | RICaD (in development) |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- Next page
- Last page
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
